prognostic effect of sildenafil in patients with severe mitral stenosis and reactive pulmonary hypertension candidate for mitral valve replacement at Tehran Heart Center

Phase 2

• Conditions: Condition 1: Reactive Pulmonary Hypertension. Condition 2: severe mitral stenosis.; Other specified pulmonary heart diseases; Mitral stenosis

• Registration Number: IRCT2014072818625N1
• Lead Sponsor: Tehran Heart Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Patients with severe mitral stenosis; Pulmonary artery pressure more than 35 mm Hg in trans esophageal echocardiography; Reactive pulmonary hypertension according right heart catheterization (difference between mean pulmonary artery pressure and Pulmonary Capillary Wedge Pressure> 12mmhg)
Exclusion criteria: Necessity of nitrate; Significant hypotension after first dose of sildensfil; Mitral regurgitation more severe than moderate degree; Necessity of aortic or tricuspid valve replacement; Concomitant Coronary artery bypasses graft surgery

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary Artery Pressure. Timepoint: 7 days before mitral valve replacement/ 6 week after mitral valve replacement. Method of measurement: Transthoracic Echocardiography.;Left Ventricular Ejection Fraction. Timepoint: 7 days before mitral valve replacement/ 6 week after mitral valve replacement. Method of measurement: Transthoracic Echocardiography.